Insider Transactions in Q1 2024 at Akebia Therapeutics, Inc. (AKBA)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 29
2024
|
Steven Keith Burke SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,169
-1.02%
|
$7,169
$1.58 P/Share
|
|
Feb 29
2024
|
John P. Butler CEO and President |
SELL
Open market or private sale
|
Direct |
46,570
-2.23%
|
$46,570
$1.58 P/Share
|
|
Feb 29
2024
|
Nicole R. Hadas SVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,974
-0.89%
|
$5,974
$1.58 P/Share
|
|
Feb 29
2024
|
Michel Dahan SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
8,661
-1.21%
|
$8,661
$1.58 P/Share
|
|
Feb 27
2024
|
John P. Butler CEO and President |
SELL
Open market or private sale
|
Direct |
37,733
-1.77%
|
$37,733
$1.52 P/Share
|
|
Feb 27
2024
|
Steven Keith Burke SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,367
-1.18%
|
$8,367
$1.52 P/Share
|
|
Feb 27
2024
|
Michel Dahan SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,744
-1.48%
|
$10,744
$1.52 P/Share
|
|
Feb 27
2024
|
Nicole R. Hadas SVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
7,411
-1.1%
|
$7,411
$1.52 P/Share
|
|
Feb 01
2024
|
Steven Keith Burke SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
24,311
-3.3%
|
$24,311
$1.68 P/Share
|
|
Feb 01
2024
|
John P. Butler CEO and President |
SELL
Open market or private sale
|
Direct |
46,489
-2.14%
|
$46,489
$1.68 P/Share
|
|
Jan 31
2024
|
Steven Keith Burke SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
202,200
+21.56%
|
-
|
|
Jan 31
2024
|
John P. Butler CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
603,500
+21.72%
|
-
|
|
Jan 31
2024
|
Nicole R. Hadas SVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
149,300
+18.08%
|
-
|
|
Jan 31
2024
|
Ellen Snow SVP, CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
149,300
+22.33%
|
-
|
|
Jan 31
2024
|
Michel Dahan SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
149,300
+17.05%
|
-
|
|
Jan 31
2024
|
Richard C Malabre Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
223,950
+50.0%
|
-
|
|
Jan 31
2024
|
Nicholas Grund Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
303,300
+50.0%
|
-
|